Glucocorticoids
The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
The most effective anti-inflammatory drugs used to treat patients with airways disease are topical glucocorticosteroids (GCs). These act on virtually all cells within the airway to suppress airway inflammation or prevent the recruitment of inflammatory cells into the airway. They also have profound effects on airway structural cells to reverse the effects of disease on their function. Glucorticosteroids act via specific receptors-the glucocorticosteroid receptor (GR)-which are a member of the nuclear receptor family. As such, many of the important actions of GCs are to modulate gene transcription through a number of distinct and complementary mechanisms. Targets genes include most inflammatory mediators such as chemokines, cytokines, growth factors and their receptors. GCs delivered by the inhaled route are very effective for most patients and have few systemic side effects. However, in some patients, even high doses of topical or even systemic GCs fail to control their disease. A number of mechanisms relating to inflammation have been reported to be responsible for the failure of these patients to respond correctly to GCs and these provide insight into GC actions within the airways. In these patients, the side-effect profile of GCs prevent continued use of high doses and new drugs are needed for these patients. Targeting the defective pathways associated with GC function in these patients may also reactivate GC responsiveness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Chronic glucocorticoid (GC) treatment represents a widely-prescribed therapy for several diseases in consideration of both anti-inflammatory and immunosuppressive activity”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [5]
In the citing paper
“Furthermore, GR-mediated feedback inhibition on the pituitary only occurs at chronic GC levels that incur adverse peripheral effects [5].”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [5]
Citations
Cites
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926
Self-citationSalmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Calverley, P. M. A., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Yates, J. C., & Vestbo, J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063070 · Cited by 3,248
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322
Pavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program
Moore, W. C., Meyers, D. A., Wenzel, S. E., Teague, W. G., Li, H., Li, X., D'Agostino, R., Castro, M., Curran-Everett, D., Fitzpatrick, A. M., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0896oc · Cited by 2,129
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Mechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847
T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma
Woodruff, P. G., Modrek, B., Choy, D. F., Jia, G., Abbas, A. R., Ellwanger, A., Arron, J. R., Koth, L. L., & Fahy, J. V. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0392oc · Cited by 1,803
Research works printed but not linked: 11
- Adcock IM, Caramori G, Chung KF (2008b) New targets for drug development in asthma. Lancet 372(9643):1073–1087 · DOI · Paper page
- Brompton Hospital/Medical Research Council Collaborative Trial (1974) Double-blind trial comparing two dosage schedules of beclomethasone dipropionate aerosol in the treatment of chronic bronchial asthma. Lancet 2(7876):303–307
- Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E, Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P (2015) TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 7(301):301
- Clark TJ (1982) Safety of inhaled corticosteroids. Eur J Respir Dis Suppl 122:235–242
- Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention. NHLBI/WHO Workshop report 2002. NHI Publication 02-3659. http://www.ginasthma.com. Accessed 11 May 2015
- Hochhaus G, Druzgala P, Hochhaus R, Huang MJ, Bodor N (1991) Glucocorticoid activity and structure activity relationships in a series of some novel 17 alpha-ether-substituted steroids: influence of 17 alpha-substituents. Drug Des Discov 8(2):117–125
- Hua G, Ganti KP, Chambon P (2016a) Glucocorticoid-induced tethered transrepression requires SUMOylation of GR and formation of a SUMO-SMRT/NCoR1-HDAC3 repressing complex. Proc Natl Acad Sci U S A 113(5):E635–E643
- Hua G, Paulen L, Chambon P (2016b) GR SUMOylation and formation of an SUMO-SMRT/NCoR1-HDAC3 repressing complex is mandatory for GC-induced IR nGRE-mediated transrepression. Proc Natl Acad Sci U S A 113(5):E626–E634
- Kupczyk M, Wenzel S (2012) U.S. and. European severe asthma cohorts: what can they teach us about severe asthma? J Intern Med 272(2):121–132
- Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R (2013) Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 11:CD003794
- Yang IA, Clarke MS, Sim EH, Fong KM (2012) Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 7:CD002991
Cited by
Items 101–131 of 131
Differential levels of thyroid hormones, cortisol, and apolipoprotein M in fatty liver disease
Zargar, A. M., Tayebinia, H., Hasanzarrini, M., Bahiraei, M., & Mohagheghi, S. (2025) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2024-0074 · Cited by 2
Machado, N. E. D. S., Banci, H. A., da Silva, L. D., Santinoni, C. D. S., de Oliveira, D. L., Ervolino, E., do Prado, R. L., & Mori, G. G. (2019) · Dental Traumatology · doi:10.1111/edt.12535 · Cited by 2
Applications of Corticosteroid Therapy in Inflammatory Rheumatic Diseases
Mușetescu, A. E., Criveanu, C., Bobirca, A. V., Florescu, A., Bumbea, A. M., & BOBIRCA, F. T. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98720 · Cited by 4
Are systemic corticosteroids needed for all asthma exacerbations?
Busse, W. W., & O’Byrne, P. M. (2025) · European Respiratory Journal · doi:10.1183/13993003.00370-2025 · Cited by 1
Titova, O. N., Кузубова, Н. А., & Lebedeva, E. S. (2019) · PULMONOLOGIYA · doi:10.18093/0869-0189-2018-28-6-693-699
Corticosteroid responsiveness and resistance in severe asthma
Bhavsar, P. K., Harmer, G., Adcock, I. M., & Chung, K. F. (2019) · European Respiratory Society eBooks · doi:10.1183/2312508x.10024218 · Cited by 3
Deng, J., Huang, E., Silver, Z. A., Zheng, E., Kavanaugh, K., Wen, A., Sanger, S., Dobransky, J. S., & Grammatopoulos, G. A. (2019) · medRxiv · doi:10.1101/19010520
“Its immunosuppressive properties and excellent ability of inhibiting a variety of inflammatory mediators make it an ideal choice for treating autoimmune diseases, such as systemic lupus erythematosus, or chronic respiratory diseases such as asthma[1, 2].”
Adcock, I. M., & Mumby, S. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-57401-7_67
李, 浩. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.111010
Adcock, I. M., & Mumby, S. E. (2021) · Springer eBooks · doi:10.1007/978-3-030-21573-6_67-1
Budesonide in the first line treatment of patients with autoimmune hepatitis
Olivas, I., Cobreros, M., Londoño, M., & Díaz‐González, Á. (2022) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2021.11.003
Glucocorticoid compounds in drug discovery by targeting glucocorticoid receptor protein
Yi, W., Wu, M., Chen, F., & Zhou, Z. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00017-6
Ekinde, S., Cambazard, F., & Cinotti, É. (2023) · Springer eBooks · doi:10.1007/978-3-031-15130-9_146
詹, 晓. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.141070
Qiu, A., Wang, J., Yang, L., Lu, X., Zhang, W., & Pan, Z. (2024) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2024.2337708
Clinical efficacy of various regimens of systemic glucocorticoids therapy in COVID-19 patients
Игоревич, В. Н., Салухов, В. В., Minakov, A. A., Prokhorova, M. O., Belyakova, T. A., & Kochukova, V. V. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-064
Glucocorticoids treatment and adverse infectious events in rheumatic diseases
Rella, V., Rotondo, C., Barile, R., Erroi, F., Cantatore, F. P., & Corrado, A. (2024) · Hospital Practice · doi:10.1080/21548331.2024.2423598 · Cited by 1
Александровна, Л. А., Olisova, O. Y., Teplyuk, N. P., Духанин, А. С., & Bakasova, V. (2024) · Russian Journal of Skin and Venereal Diseases · doi:10.17816/dv636711
Tsige, A. W., Simegn, K., Beyene, D. A., Ayenew, K. D., Wondmkun, Y. T., Endalifer, B. L., Ambaye, A. S., Dagnew, S. B., & Ayele, S. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-81425-8
Patriarca, E. J., D’Aniello, C., Cesare, D. D., Cobellis, G., & Minchiotti, G. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17040504
Ocaranza, F. J., & Sáez, J. C. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1012583
Crosstalk Between H2S and Hormones: The Bilateral Relationship and Molecular Mechanisms
Yang, G. (2025) · Handbook of experimental pharmacology · doi:10.1007/164_2025_756
Kong, Q., Mo, S., Wang, W., Tang, Z., Wei, Y., Du, Y., Liu, B., Kong, L., Lv, Y., & Dong, J. (2020) · Figshare · doi:10.6084/m9.figshare.12916831
Steger, L., Liquet, B., Agyemang, K., Freistühler, M., Ieva, A. D., Stummer, W., Ertmer, C., & Molina, E. S. (2026) · Brain and Spine · doi:10.1016/j.bas.2026.105967
“Still, their mineralocorticoid and glucocorticoid potencies vary due to differences in chemical structure and modifications (Adcock and Mumby, 2016; Samuel et al., 2017) (Table 3).”
Kobayashi, M., Yamada, T., Ueyama, S., Yamamoto, Y., Sugaya, A., Hiroshima, Y., Mamiya, T., Hattori, J., Akiyama, S., Mathis, B. J., et al. (2026) · JGH Open · doi:10.1002/jgh3.70365 · Cited by 1
Role of the endocannabinoid system in exercise motivation
Redon, B. (2021) · theses.fr (ABES) · doi:10.70675/844c9d99zd3c6z4550z97a6zebab239b226c
The role of PRMT5-mediated methylation of steroid receptor in breast Cancer
Pham, T. H. (2022) · theses.fr (ABES) · doi:10.70675/f6e3d282z871dz4ffaz87bazb04f22d60d50 · Cited by 1
Glucocorticoid receptor activity in triple negative breast cancer
Noureddine, L. M. (2022) · theses.fr (ABES) · doi:10.70675/13ab50cfz7edbz4a44z918aza657b9614a4d · Cited by 1
Zhang, Q., Li, Y., Yu, B., Wang, C., Zhang, L., & Yan, B. (2026) · Asia Pacific Allergy · doi:10.5415/apallergy.0000000000000293
Maideen, N. M. P., Balasubramanian, R., Sirajudeen, M. N., Nabi, R., Mohamed, A. P. R., & Dhanabalan, K. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02647-7
Maideen, N. M. P., Balasubramanian, R., Kandasamy, K., & Hameed, M. F. S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02715-y
Metadata
- Authors
- Adcock, I. M., & Mumby, S.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Adcock, Ian M.
- Venue
- Handbook of experimental pharmacology
- Publisher
- Springer International Publishing
- Published
- 2016
- Volume
- 237
- Pages
- 171-196
- ISSN
- 0171-2004 (ISSN-L)
- 1865-0325
- OpenAlex
- W4211105534
- Cited by
- 131
- References
- 137
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 19 · 2023: 15 · 2022: 14 · 2021: 30 · 2020: 15 · 2019: 13 · 2018: 1 · 2017: 1 · 2016: 1
- FWCI
- 21.63
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Handbook of experimental pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- Wellcome Trust
- British Heart Foundation (PG/14/27/30679)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- glucocorticoids, topical glucocorticosteroids, airway inflammation, glucocorticoid receptor, nuclear receptors, gene transcription, chemokines, cytokines, inhaled corticosteroids, glucocorticoid resistance, glucocorticoid adverse effects, anti-inflammatory agents
- MeSH terms
- Animals, Asthma, Glucocorticoids, Humans, Receptors, Glucocorticoid, Oxidative Stress
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.